About: Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by R Kieburtz published 1996 in Annals of Neurology

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 1996 (uk) im Januar 1996 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by R Kieburtz published 1996 in Annals of Neurology (en)
publication date	wds:Q67243046-63A7A43D-AABF-4EF4-88BE-E620E65F13EC
publication date	1996-01-01 00:00:00Z (xsd:dateTime)
rdfs:label	Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (en) Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (nl)
skos:prefLabel	Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (en) Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (nl)
name	Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (en) Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (nl)
author	wds:Q67243046-EF7D1CE0-E366-4476-9FB5-D8FAF4B08350
author	R Kieburtz
title	wds:Q67243046-D96405A5-999D-42D4-A83B-4B077BCEA6DE
title	Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. (en)
instance of	wds:Q67243046-4D07E7E8-58F3-49CE-80AF-5E68BA48635C
instance of	scholarly article
main subject	wds:Q67243046-048DEEA7-67BD-4980-9101-4E5DB0950462
main subject	Parkinson's disease
PubMed ID	wds:Q67243046-8219045D-76AD-4F93-9CFE-7F4D0521569F
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8687199
PubMed ID	8687199
published in	wds:Q67243046-30DECAA5-A6DC-4C32-AD8F-4E29D3B90062
published in	Annals of Neurology
DOI	wds:Q67243046-A558A5BD-CC45-46A0-97B8-E37C7E5217BA
DOI	http://dx.doi.org/10.1002/ANA.410400116
DOI	10.1002/ANA.410400116
Semantic Scholar paper ID	wds:Q67243046-47FA453B-E0E5-4E3B-8995-91CB494F7C73
Semantic Scholar paper ID	c6d0d9de31f6b1ab08fb20e95190bb858a85b62e
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q67243046
is cites work of	MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway Emerging therapies in the pharmacological treatment of Parkinson's disease α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease Progression of motor symptoms in Parkinson's disease The therapeutic potential of monoamine oxidase inhibitors Progression of Parkinson's disease in the clinical phase: potential markers The natural history of Parkinson’s disease A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease Does levodopa slow or hasten the rate of progression of Parkinson's disease? Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease Safety of selegiline (deprenyl) in the treatment of Parkinson's disease Monoamine oxidase and catechol-O-methyltransferase inhibitors Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients Perspectives on MAO-B in aging and neurological disease: where do we go from here? Alternatives to levodopa in the initial treatment of early Parkinson's disease Deep brain stimulation for early-stage Parkinson's disease: an illustrative case Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques Design and analysis of two-period studies of potentially disease-modifying treatments. The clinical progression of Parkinson's disease Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease Interventions for fatigue in Parkinson's disease An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis Protection against Parkinson's disease progression: clinical experience Adjunctive therapy in Parkinson's disease: the role of rasagiline Monoamine oxidase B inhibitors for early Parkinson's disease Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis Initiation of pharmacological therapy in Parkinson's disease: when, why, and how 90 years of monoamine oxidase: some progress and some confusion. 8-Benzyltetrahydropyrazino[2,1-f]purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases. A Stage-Based Approach to Therapy in Parkinson's Disease Investigational agents in the treatment of Parkinson's disease: focus on safinamide
is cites work of	wds:Q34585156-49B5BA89-D7A3-4320-95EB-D3AA32100E3B wds:Q24671046-95E319FD-044A-4911-9909-364270CA4FEC wds:Q34628386-65D63DAF-FF8A-4917-BD15-30CC3DEE6BE7 wds:Q33545299-B3C5139A-4CAD-45E3-8340-236D518E9CA9 wds:Q35613111-AE875BE8-5560-4916-A71D-A369A1EAD21E wds:Q64228916-26D49309-C1A5-4B36-85C6-8429DEEC9D41 wds:Q36255233-BA1DF33B-D839-44B7-9A05-EE6D11BD1A04 wds:Q37736512-CCB3FA9E-D61E-48E9-A289-E80A2C3A2BEC wds:Q53356323-9B6EA91D-E98D-456E-B3CC-B1D076068282 wds:Q24246514-E17EEAB8-A0D2-4E64-BF30-854E88BD675E wds:Q28277143-4545FC1E-44AC-44E5-A244-05E31C4CB512 wds:Q24186581-C4E40DF1-B657-4D50-AD96-38D61A0AFA10 wds:Q37685672-AAEC77C8-FD16-4DF3-B585-44B2A0EA5D20 wds:Q37358676-E1AF9EB6-5C0E-486D-89B2-0FF447E9D012 wds:Q37631962-F6EF4FA0-BDF5-40AB-A89F-CDB4E2A26CD1 wds:Q28271492-177F3360-2C3C-415D-8AAF-F1A2B3E0DBDB wds:Q37131239-18384D9D-6201-4FA6-B8B8-61C3590502B3 wds:Q37974751-5B093DA1-9093-413A-A0B9-8ABB635D065D wds:Q53413619-CD57F9F8-8751-4A11-B513-F8EE03235C23 wds:Q81554401-3E3E4A07-7EAC-48FE-A285-9ACF3F0EB7FF wds:Q92753479-B99C0898-89C8-422A-B2CD-1C4CEDD414F5 wds:Q21090919-9F8C88F3-6CFD-4F05-B6BF-DF3B4501D155 wds:Q34027880-9AE28B44-B1C0-46D1-8167-EDF8426F62C8 wds:Q24561822-1191D04E-68B6-4990-9810-99B27AEC1944 wds:Q35166780-54C9D73D-2457-40B4-8725-AB36C7CCF2CA wds:Q37963572-652CAB35-8C93-4D0A-8BC2-C9D4D86A4CC0 wds:Q48171351-6D6F7328-4F52-4D7C-A952-EF8A75476184

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software